Patents by Inventor Ramakrishna Nirogi
Ramakrishna Nirogi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11622967Abstract: The present invention provides new methods of treatment for narcolepsy, excessive daytime sleepiness, obstructive sleep apnea, circadian rhythm sleep disorders, sleep and vigilance disorders associated with Parkinson's disease, multiple sclerosis, dementia or attention deficit hyperactivity disorder by administering a therapeutically effect amount of histamine-3 receptor (H3R) inverse agonist, N-[4-(1-Cyclobutylpiperidin-4-yloxy)phenyl]-2-(morpholin-4-yl)acetamide or a pharmaceutically acceptable salt thereof. The present invention further provides use of the said compounds in the manufacture of medicament intended for the treatment of the disorders described herein.Type: GrantFiled: August 1, 2018Date of Patent: April 11, 2023Assignee: SUVEN LIFE SCIENCES LIMITEDInventors: Ramakrishna Nirogi, Anil Karbhari Shinde, Vijay Sidram Benade, Saivishal Daripelli, Pradeep Jayarajan, Jyothsna Ravula, Venkateswarlu Jasti
-
Publication number: 20230000859Abstract: The present invention provides a method for treating behavioral and psychological symptoms in patients with dementia comprising administering an effective dose of pure 5-HT6 receptor antagonist and acetylcholinesterase inhibitor or NMDA receptor antagonist. The present invention also relates to a pharmaceutical combination comprising pure 5-HT6 receptor antagonist and acetylcholinesterase inhibitor or NMDA receptor antagonist, in particular for treating behavioral and psychological symptoms in patients with dementia. The present invention further provides use of the said compounds in the manufacture of a medicament, and a pharmaceutical composition comprising the said compounds intended for the treatment of disorders described herein.Type: ApplicationFiled: December 2, 2020Publication date: January 5, 2023Applicant: SUVEN LIFE SCIENCES LIMITEDInventors: Ramakrishna NIROGI, Anil Karbhari SHINDE, Veena REBALLI, Pradeep JAYARAJAN, Renny ABRAHAM, Venkateswarlu JASTI, Rajesh BADANGE, Vijay Sidram BENADE
-
Publication number: 20220409614Abstract: The present invention provides a method for treating behavioral and psychological symptoms in patient with dementia comprising administering an effective dose of pure 5-HT6 receptor antagonist, masupirdine or a pharmaceutically acceptable salt thereof either alone or in combination with an acetylcholinesterase inhibitor such as donepezil and NMDA (N-Methyl-D-aspartate) receptor antagonist, memantine. The present invention further provides use of the said compound in the manufacture of a medicament and pharmaceutical compositions comprising the said compounds intended for the treatment of the disorders described herein.Type: ApplicationFiled: December 2, 2020Publication date: December 29, 2022Applicant: SUVEN LIFE SCIENCES LIMITEDInventors: Ramakrishna NIROGI, Anil Karbhari SHINDE, Pradeep JAYARAJAN, Satish JETTA, Raghava Chowdary PALACHARLA, Santosh Kumar PANDEY, Abdul Rasheed MOHAMMED, Vijay Sidram BENADE, Vinod Kumar GOYAL, Ramkumar SUBRAMANIAN, Jyothsna RAVULA, Venkateswarlu JASTI
-
Publication number: 20220387451Abstract: The present invention relates to a pharmaceutical composition comprising solid dispersion of amorphous abiraterone acetate and one or more pharmaceutically acceptable excipients, having improved solubility, stability, bioavailability, and no positive food effect. The present invention also relates to a method for its preparation, a dosage form comprising such compositions, and the use of the said composition or dosage form as a medicament for the treatment of prostate cancer.Type: ApplicationFiled: November 13, 2020Publication date: December 8, 2022Applicant: SUVEN LIFE SCIENCES LIMITEDInventors: Ramakrishna NIROGI, Dhanunjay Kumar DOGIPARTI, Koteshwara MUDIGONDA, Jyothsna RAVULA, Venkateswarlu JASTI
-
Patent number: 11458135Abstract: The present invention relates to pure 5-HT6 receptor antagonists, or the pharmaceutically acceptable salt(s) thereof in combination with or as adjunct to acetylcholinesterase inhibitors and their use in the treatment of cognitive disorders. The invention further provides the pharmaceutical composition containing the said combination.Type: GrantFiled: August 3, 2016Date of Patent: October 4, 2022Assignee: Suven Life Sciences LimitedInventors: Ramakrishna Nirogi, Anil Karbhari Shinde, Pradeep Jayarajan, Gopinadh Bhyrapuneni, Ramasastri Kambhampati, Venkateswarlu Jasti
-
Patent number: 11278530Abstract: The present invention relates to compounds of formula (I), or their isotopic forms, stereoisomers, tautomers or pharmaceutically acceptable salt (s) thereof as muscarinic M1 receptor positive allosteric modulators (M1 PAMs). The present invention describes the preparation, pharmaceutical composition and the use of compound formula (I).Type: GrantFiled: October 26, 2018Date of Patent: March 22, 2022Assignee: Suven Life Sciences LimitedInventors: Ramakrishna Nirogi, Abdul Rasheed Mohammed, Anil Karbhari Shinde, Shankar Reddy Gagginapally, Durga Malleshwari Kancharla, Santosh Kumar Pandey, Renny Abraham, Venkateswarlu Jasti
-
Patent number: 11253514Abstract: The present invention relates to a combination of pure 5-HT6 receptor antagonist, acetylcholinesterase inhibitor and NMDA receptor antagonist. Also, the present invention provides pure 5-HT6 receptor (5-HT6R) antagonists, or the pharmaceutically acceptable salt(s) thereof in combination with or as adjunct to acetylcholinesterase inhibitor and N-Methyl-D-aspartate (NMDA) receptor antagonist and their use in the treatment of cognitive disorders. The invention further provides the pharmaceutical composition containing the said combination.Type: GrantFiled: August 3, 2016Date of Patent: February 22, 2022Assignee: Suven Life Sciences LimitedInventors: Ramakrishna Nirogi, Anil Karbhari Shinde, Pradeep Jayarajan, Gopinadh Bhyrapuneni, Ramasastri Kambhampati, Venkateswarlu Jasti
-
Patent number: 11234979Abstract: The present invention relates to compounds of formula (I), or their isotopic forms, stereoisomers, tautomers or pharmaceutically acceptable salt (s) thereof as muscarinic M1 receptor positive allosteric modulators (M1 PAMs).Type: GrantFiled: October 17, 2018Date of Patent: February 1, 2022Assignee: Suven Life Sciences LimitedInventors: Ramakrishna Nirogi, Abdul Rasheed Mohammed, Anil Karbhari Shinde, Srinivas Ravella, Vanaja Middekadi, Vinod Kumar Goyal, Pradeep Jayarajan, Saivishal Daripelli, Venkateswarlu Jasti
-
Publication number: 20210386727Abstract: The present invention relates to new uses of a 5-HT4 receptor agonist, specifically Isopropyl-3-{5-[1-(3-methoxypropyl)piperidin-4-yl]-[1,3,4] oxadiazol-2-yl}-1H-indazole (Compound-1) or a pharmaceutically acceptable salts thereof, for the treatment of dementia due to menopause, senile dementia, cognitive deficits associated with schizophrenia, depression, chemotherapy-induced cognitive impairment, and behavioral and psychological symptoms of dementia such as apathy/indifference, agitation, aggression, depression, anxiety, irritability/lability, dysphoria, aberrant motor behavior, delusions, hallucinations, elation/euphoria, psychosis, disinhibition, sleep and night time behavior disorders or appetite and eating disorders. The present invention further provides use of the said compounds in the manufacture of medicament intended for the treatment of the disorders described herein.Type: ApplicationFiled: October 17, 2019Publication date: December 16, 2021Applicant: SUVEN LIFE SCIENCES LIMITEDInventors: Ramakrishna NIROGI, Abdul Rasheed MOHAMMED, Anil Karbhari SHINDE, Venkata Ramalingayya GRANDHI, Pradeep JAYARAJAN, Vijay BENADE, Gopinadh BHYRAPUNENI, Venkateswarlu JASTI
-
Publication number: 20210369685Abstract: The present invention relates to compounds of formula (I), or their isotopic forms, stereoisomers, tautomers or pharmaceutically acceptable salt (s) thereof as muscarinic M1 receptor positive allosteric modulators (M1 PAMs). The present invention describes the methods of preparation, pharmaceutical composition, combinations and the use of compound formula (I), their stereoisomers, isotopic forms or pharmaceutically acceptable salts thereof.Type: ApplicationFiled: November 21, 2018Publication date: December 2, 2021Applicant: SUVEN LIFE SCIENCES LIMITEDInventors: Ramakrishna NIROGI, Anil Karbhari SHINDE, Abdul Rasheed MOHAMMED, Rajesh Kumar BADANGE, Raghava Choudary PALACHARLA, Venkateswarlu JASTI
-
Publication number: 20210346374Abstract: The present invention relates to an immediate release (IR) pharmaceutical composition comprising 1-[(2-bromophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl) methyl]-1H-indole or pharmaceutically acceptable salt (s) and one or more pharmaceutically acceptable excipients. The present invention also relates to methods of preparation of said pharmaceutical compositions.Type: ApplicationFiled: July 16, 2021Publication date: November 11, 2021Applicant: SUVEN LIFE SCIENCES LIMITEDInventors: Ramakrishna NIROGI, Koteshwara MUDIGONDA, Dhanunjay Kumar DOGIPARTI, Venkateswarlu JASTI
-
Publication number: 20210338661Abstract: The present invention relates to new uses of a pure 5-HT6 receptor antagonist, specifically 1-[(2-Bromophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]-1H-indole or a pharmaceutically acceptable salts thereof, for the treatment of dementia due to menopause, senile dementia, vascular dementia, chemotherapy-induced cognitive impairment and behavioral changes in dementia such as agitation, aggression, depression, anxiety, psychosis, disinhibition, or sleep disturbances. The present invention further provides use of the said compounds in the manufacture of medicament intended for the treatment of the disorders described herein.Type: ApplicationFiled: June 29, 2018Publication date: November 4, 2021Applicant: SUVEN LIFE SCIENCES LIMITEDInventors: Ramakrishna NIROGI, Venkata Ramalingayya GRANDHI, Pradeep JAYARAJAN, Venkateswarlu JASTI
-
Publication number: 20210340148Abstract: The present invention relates to compounds of formula (I), or their isotopic forms, stereoisomers, tautomers or pharmaceutically acceptable salt (s) thereof as muscarinic M1 receptor positive allosteric modulators (M1 PAMs). The present invention describes the preparation, pharmaceutical composition and the use of such compounds.Type: ApplicationFiled: October 16, 2019Publication date: November 4, 2021Applicant: SUVEN LIFE SCIENCES LIMITEDInventors: Ramakrishna NIROGI, Abdul Rashee MOHAMMED, Anil Karbhari SHINDE, Srinivasa Rao RAVELLA, Ramkumar SUBRAMANIAN, Venkateswarlu JASTI
-
Patent number: 11116764Abstract: The present invention relates to pure 5-HT6 receptor antagonist or the pharmaceutically acceptable salt(s) thereof in combination with or as adjunct to NMDA receptor antagonist and their use in the treatment of cognitive disorders. The invention further relates to the pharmaceutical composition containing the said combination.Type: GrantFiled: August 3, 2016Date of Patent: September 14, 2021Assignee: Suven Life Sciences LimitedInventors: Ramakrishna Nirogi, Anil Karbhari Shinde, Pradeep Jayarajan, Gopinadh Bhyrapuneni, Ramasastri Kambhampati, Venkateswarlu Jasti
-
Publication number: 20210213026Abstract: The present invention provides new methods of treatment for narcolepsy, excessive daytime sleepiness, obstructive sleep apnea, circadian rhythm sleep disorders, sleep and vigilance disorders associated with Parkinson's disease, multiple sclerosis, dementia or attention deficit hyperactivity disorder by administering a therapeutically effect amount of histamine-3 receptor (H3R) inverse agonist, N-[4-(1-Cyclobutylpiperidin-4-yloxy)phenyl]-2-(morpholin-4-yl)acetamide or a pharmaceutically acceptable salt thereof. The present invention further provides use of the said compounds in the manufacture of medicament intended for the treatment of the disorders described herein.Type: ApplicationFiled: August 1, 2018Publication date: July 15, 2021Applicant: SUVEN LIFE SCIENCES LIMITEDInventors: Ramakrishna NIROGI, Anil Karbhari SHINDE, Vijay Sidram BENADE, Saivishal DARIPELLI, Pradeep JAYARAJAN, Jyothsna RAVULA, Venkateswarlu JASTI
-
Patent number: 11040026Abstract: The present invention relates to compounds of formula (I), or their isotopic forms, stereoisomers, tautomers or pharmaceutically acceptable salt(s) thereof as muscarinic M1 receptor positive allosteric modulators (M1 PAMs). The present invention describes the preparation, pharmaceutical composition and the use of compound formula (I).Type: GrantFiled: August 31, 2017Date of Patent: June 22, 2021Assignee: Suven Life Sciences LimitedInventors: Ramakrishna Nirogi, Anil Karbhari Shinde, Abdul Rasheed Mohammed, Rajesh Kumar Badange, Pradeep Jayarajan, Gopinadh Bhyrapuneni, Venkateswarlu Jasti
-
Patent number: 10973831Abstract: The present invention relates to fluoropiperidine compounds of formula (I), their stereoisomers, isotopic forms or pharmaceutically acceptable salts thereof as 5-HT6 receptor antagonists. In particular the present invention discloses the methods of preparation, pharmaceutical composition, combinations and use of fluoropiperidine compounds, their stereoisomers, isotopic forms or pharmaceutically acceptable salts thereof.Type: GrantFiled: August 6, 2018Date of Patent: April 13, 2021Assignee: SUVEN LIFE SCIENCES LIMITEDInventors: Ramakrishna Nirogi, Anil Karbhari Shinde, Abdul Rasheed Mohammed, Rajesh Kumar Badange, Kumar Bojja, Vinod Kumar Goyal, Santosh Kumar Pandey, Jagadeesh Babu Thentu, Venkateswarlu Jasti
-
Publication number: 20200297703Abstract: The present invention relates to compounds of formula (I), or their isotopic forms, stereoisomers, tautomers or pharmaceutically acceptable salt (s) thereof as muscarinic M1 receptor positive allosteric modulators (M1 PAMs). The present invention describes the preparation, pharmaceutical composition and the use of compound formula (I).Type: ApplicationFiled: October 26, 2018Publication date: September 24, 2020Applicant: SUVEN LIFE SCIENCES LIMITEDInventors: Ramakrishna NIROGI, Abdul Rasheed MOHAMMED, Anil Karbhari SHINDE, Shankar Reddy GAGGINAPALLY, Durga Malleshwari KANCHARLA, Santosh Kumar PANDEY, Renny ABRAHAM, Venkateswarlu JASTI
-
Publication number: 20200237761Abstract: The present invention relates to compounds of formula (I), or their isotopic forms, stereoisomers, tautomers or pharmaceutically acceptable salt (s) thereof as muscarinic M1 receptor positive allosteric modulators (M1 PAMs). The present invention describes the preparation, pharmaceutical composition and the use of compound formula (I).Type: ApplicationFiled: October 17, 2018Publication date: July 30, 2020Applicant: SUVEN LIFE SCIENCES LIMITEDInventors: Ramakrishna NIROGI, Abdul Rasheed Rasheed MOHAMMED, Anil Karbhari SHINDE, Srinivas RAVELLA, Vanaja MIDDEKADI, Vinod Kumar GOYAL, Pradeep JAYARAJAN, Saivishal DARIPELLI, Venkateswarlu JASTI
-
Publication number: 20200155560Abstract: The present invention relates to fluoropiperidine compounds of formula (I), their stereoisomers, isotopic forms or pharmaceutically acceptable salts thereof as 5-HT6 receptor antagonists. In particular the present invention discloses the methods of preparation, pharmaceutical composition, combinations and use of fluoropiperidine compounds, their stereoisomers, isotopic forms or pharmaceutically acceptable salts thereof.Type: ApplicationFiled: August 6, 2018Publication date: May 21, 2020Applicant: SUVEN LIFE SCIENCES LIMITEDInventors: Ramakrishna NIROGI, Anil Karbhari SHINDE, Abdul Rasheed MOHAMMED, Rajesh Kumar BADANGE, Kumar BOJJA, Vinod Kumar GOYAL, Santosh Kumar PANDEY, Jagadeesh Babu THENTU, Venkateswarlu JASTI